Super Naturals: the high-tech natural beauty brands changing the face of modern skincare – Evening Standard

The latest lifestyle, fashion and travel trends

A high-end bio-beauty boom is in full bloom thanks to a host of revolutionary brands set on changing the face of modern skincare. These are the five to know...

Hailing from the Napa Valley, where founder April Gargiulo spent two years researching and developing her Holy Grail skincare products using the same meticulous approach her family took to their fine wine business, Vintners Daughter champions just two products that promise dramatic, multi-correctional results using some of the worlds most active organic and foraged botanicals. The original Active Botanical Serum (175) is hailed as the face oils to end all face oils and is built around the brands signature Phyto Radiance Infusion. This process starts with consciously grown whole plants such as calendula and super green alfalfa, known in ancient times as the foods of life, which undergo a methodical three-week long extraction to glean every last drop of their nutritional benefits. Just five drops using the brands 30-second Push/Press Method of application promises to deliver visible radiance, brightness and unparalleled nourishment particularly when used in conjunction with its preparatory Active Treatment Essence (210) (goop.com).

The undisputed Queen of Green, Tata Harper is a pioneer of the farm-to-face beauty movement with all-natural formulations handcrafted in the brands laboratory in Vermont and bottles stamped with a code to trace how fresh your product is and who it was made by. The beauty editors favourite is going one step further with the launch of its Supernaturals 2.0 line of six products boasting 155 ultramodern green ingredients from 46 countries and of course, no synthetic chemicals. The Elixir Vitae Serum (391) alone boasts 34 new radical engineered ingredients from 25 countries, including kelp polymers from France developed to target cellular ageing. Other highlights from the range include the Concentrated Brightening Serum (257), which contains 24 ingredients to hydrate, 17 to reduce wrinkles, 15 to brighten and 13 to even skin tone, and the Boosted Contouring Serum (257), designed to lift, firm and restore youthful elasticity with a combination of Edelweiss stem cells and skin revitalising pomegranate. (tataharperskincare.com)

The brainchild of cosmetologist Anna Buonocore and naturalist Jeanette Thottrup, Seed To Skin believes that effective skincare is threefold. Firstly, that wild ingredients foraged from the land and sea used in conjunction with those sourced from its organic Tuscan farm are among the most potent nature has to offer. Secondly, that just like feeding your body skin requires a healthy, balanced diet and formulas that neither starve nor overload with any one element. Finally, that the most effective absorption relies on a precise mix of perfectly-sized molecules to ensure each ingredient is delivered exactly where it needs to go. As a result, its award-winning product line is loaded with game changers try The AlcheMist Super Active Serum Spray (145) to feed your skin a nutrient-rich drink whenever it needs a boost, or the Black Magic Detoxifying Oxygen Therapy Mask (119) which contains activated charcoal and volcanic clay for a one-stop facial in a jar (libertylondon.com).

(Wildsmith )

Inspired by the arboretums progressive approach to cultivation at Hampshires Heckfield Place and named after its mastermind William Walker Wildsmith, this ethical crafted-in-England skincare brand is designed for those who desire natural products but demand clinical results. Exclusive to Harrods beauty halls, the hero additions to its product line-up include the Platinum Booster (175) a powerful skin-firming treatment powered by encapsulated oxygen and moss cell cultures and a reviving, collagen-boosting Copper Peptide Cream and Serum Duo (150) which delivers a luminous finish to your complexion and comes in a compostable mycelium box (wildsmithskin.com; harrods.com).

After turning to flower arranging as a weekly dose of mindfulness, beauty entrepreneur Kelly S Chung endeavoured to harness the healing power of nature or Flower Therapy, as she has coined it in another form; and Femmue was born. Fusing K-beauty innovation with a clean beauty ethos and the cellular energy of plants, the camellia flower is at the heart of the range and renowned for its antioxidant and restorative qualities. The Divine Camlia Facial Oil (100) is the purest form with 99.8 per cent camellia seed oil, while other must-try products in the line include the bestselling Flower Infused Fine Mask (40) formulated with camellia petals, geranium oil and cactus extract and the lavender-loaded Brilliant Cleansing Oil (73) (net-a-porter.com).

View post:

Super Naturals: the high-tech natural beauty brands changing the face of modern skincare - Evening Standard

Read more
What is Hereditary Persistence of Fetal Hemoglobin? – News-Medical.net

What is fetal hemoglobin?

Fetal hemoglobin (HbF) is the most dominant form of hemoglobin (Hb) in fetuses and persists until birth, at which time the production of adult Hb is upregulated. Both fetal and adult Hb contain alpha () globin chains; however, in adult Hb, the gamma () globin chains are replaced with beta () globin.

Image Credit: Phonlamai Photo / Shutterstock.com

Six months after birth, HbA is the dominant form of Hb, and any conditions which affect Hb become clinically apparent. At six months, HbF comprises less than 5% of the total Hb, and it continues to fall, reaching the adult level of less than 1% by the age of 2.

The switch from fetal to adult Hb production does not occur to completion, nor is it irreversible. All adults retain the capacity to produce some HbF, which steadily declines throughout adult life. The degree to which HbF persists tends to vary greatly between adults, and this variability is under genetic control.

The persistence of relatively high levels of HbF production is not clinically harmful in healthy individuals; however, in patients suffering from conditions that affect the quality of HbA (such as those suffering from sickle cell disease or -thalassemia), the condition can offer an advantage.

High HbF levels confer significant benefits namely milder disease progression and fewer complications. Therefore, HbF has an ameliorating effect, which has prompted several approaches to therapeutic agent production in patients with mutations affecting adult HbA quality. These approaches include, for example, the pharmacological and gene transfer for HbF synthesis reactivation.

The residual HbF in adults is distributed unevenly amongst the red blood cells; cells that contain measurable quantities are referred to as F cells (FC). These typically contain a mean cell volume (MCV) of between 80-90 fl, compared to larger fetal cells with an MCV of approximately 125 fl. Within the FC, HbF only comprises a small portion of the total Hb.

Detection of FC occurs traditionally by an acid illusion method developed by Kleihauer; however, a much more sensitive immunofluorescence-based method uses an anti- globin antibody for use on fixed red blood cell smears, or via fluorescence-activated cell sorting (FACS), following labeling of the intracellular HbF.

Surveys of healthy blood donors across population groups demonstrate that levels of FC and HbF can vary more than 20-fold, and the distribution is both continuous and positively skewed. Furthermore, family studies show levels of HbF tend to be heritable, although the inheritance patterns are not clear. Twin studies show that the correlation between HbF and FC is genetically controlled, with a heritability of 0.89.

Hereditary persistence of fetal hemoglobin is a condition in which levels of HbF persist at levels greater than typically expected (less than 1%). In hereditary persistence of fetal hemoglobin (HPFH), this HbF percentage varies from levels as low as 0.8-1.0% to approximately 30% of the total hemoglobin.

However, the percentage of HbF can climb as high as 100% in homozygotes (individuals with two copies of the affected gene) for delta beta () thalassemia, another form of thalassemia characterized by defective mutations in the chains of hemoglobin.

This condition is inherited in a mendelian fashion and is caused either by large deletions in the gene that controls the subunit for HbA or by point mutations in the promoter (site of gene expression) of the globin genes. The condition is both benign and asymptomatic. The condition is classified as either pancellular / homocellular or heterocellular, based on the hemoglobin distribution pattern.

Pancellular conditions affect all cells, whereas heterocellular conditions affect some cells, and homocellular conditions affect similar groups of cells. In heterocellular HPFH, the level of HBF can range from 10 to 40%. On the other hand, the levels of HbF in heterocellular HPFH are only modestly elevated, and levels of hemoglobin are unevenly distributed amongst the red blood cells.

Pathogenic increases in HbF, which are distributed heterogeneously, are associated with drug use, malignancies, and hemoglobinopathies. Drugs such as hydroxyurea and pomalidomide increase HPFH. Trisomy 13, a chromosome disorder, is associated with a switch from HbF to HbA with persistently elevated HbF quantities in the blood.

Some patients with -thalassemia, which is caused by reduced or absent synthesis of the globin chains of hemoglobin which reduces the oxygen-carrying capacity of red blood cells, contain elevated levels of HbF that correlate with the degree of chain deficiency as well as a co-inheritance of thalassemia.

This protects against the deleterious effect of - globin chain precipitation, caused by decreased cell: cell chain ratios, which result in unstable tetramers, which are poor carriers of O2.

Other conditions in which elevated HbF is seen in patients include leukemia, following chemotherapy, as well as in patients treated for severe iron deficiency anemia due to acute blood loss. This occurs as a result of 'stressed' hematopoiesis or erythropoiesis (hemoglobin or red blood cell production, respectively). Patients with inherited bone marrow failure syndromes additionally show altered HbF as part of stressed synthesis blood components.

The benefits of HPFH are most noticeable when it co-exists with sickle cell or thalassemia. These conditions cause diminished oxygen-carrying capacity of red blood cells due to unstable chains that form part of the tetramer of the oxygen-binding hemoglobin. As a result, the production of HbF alleviates this issue, as HbF contains rather than chains, which are affected in adult Hb.

Owing to its ability to alleviate the severity of hemoglobinopathies in thalassemias, hereditary persistence of fetal hemoglobin tends to be selected for in populations in which these disorders are prevalent, such as people of African and Greek descent.

Friedman S, Schwartz. Hereditary persistence of foetal haemoglobin with beta-chain synthesis in cis position (gamma-beta+-HPFH) in a negro family". Nature. 1976 doi:10.1038/259138a0

Patel, S. et al. Inheritance of Hereditary Persistence of Fetal Haemoglobin (HPFH) in a Family of Western Odisha, India. J Clin Diagn Res. 2015. doi: 10.7860/JCDR/2015/12878.6548

Sokolova, A. et al. Hereditary persistence of hemoglobin F is protective against red cell sickling. A case report and brief review. Hematology/Oncology and Stem Cell Therapy. doi: 10.1016/j.hemonc.2017.09.003

Collins, F.S. et al. gamma beta+ hereditary persistence of fetal hemoglobin: cosmid cloning and identification of a specific mutation 5 to the G gamma gene. Proc Natl Acad Sci USA. 1984. doi: 10.1073/pnas.81.15.4894

Thein, S. Discovering the genetics underlying foetal haemoglobin production in adults. British Journal of Haematology. 2009. doi: 10.1111/j.1365-2141.2009.07650.x

Read more:

What is Hereditary Persistence of Fetal Hemoglobin? - News-Medical.net

Read more
Facilitating Drug Discovery With Induced Pluripotent Stem Cells – News-Medical.net

Download Axols free white paper - "Induced Pluripotent Stem Cells: recapitulating disease to facilitate drug discovery"

Understand more about how iPSC-derived cells can improve any drug development research program by supplying a physiologically relevant model, which is capable of representing a disease population. This enables research in multiple stages of the development pipeline.

This white paper comprises cases wherein iPSC-derived cells have been utilized for target identification, target validation, lead optimization and safety testing, as a means of reducing failure rates of drug candidates.

Download Axols white paper and find out how hiPSCs are an essential tool in drug discovery.

Axol specializes in human cell culture.

Axol produces high quality human cell products and critical reagents such as media and growth supplements. We have a passion for great science, delivering epic support and innovating future products to help our customers advance faster in their research.

Our expertise includes reprogramming cells to iPSCs and then differentiating to various cell types. We supply differentiated cells derived from healthy donors and patients of specific disease backgrounds. As a service, we also take cells provided by customers (primary or iPSC) and then do the reprogramming (when necessary) and differentiation. Clearly, by offloading the burden of generating cells, your time is freed up to focus on the research. Axol holds the necessary licenses that are required to do iPSC work.

The package wouldn't be complete without optimized media, coating solutions and other reagents. Our in-house R&D team works hard to improve on existing media and reagents as well as innovate new products for human cell culture. We also supply a growing range of human primary cells; making Axol your first port of call for your human cell culture needs.

Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Read the rest here:

Facilitating Drug Discovery With Induced Pluripotent Stem Cells - News-Medical.net

Read more
New protocol could signal shift in bone regenerative medicine – Yahoo Finance

A new, safe and efficient way to coax stem cells into bone cells is reported in a recently published article from STEM CELLS Translational Medicine (SCTM).

DURHAM, N.C., Jan. 6, 2020 /PRNewswire-PRWeb/ -- A new, safe and efficient way to coax stem cells into bone cells is reported in a recently published article from STEM CELLS Translational Medicine (SCTM). The protocol, developed by researchers at the University of Sydney, Australian Research Centre (ARC) for Innovative BioEngineering, could lead to a shift in the treatment of bone regenerative medicine.

Large bone defects and loss due to cancer or trauma can result in scar tissue that impairs the bones' ability to repair and regenerate. The current gold standard therapy, autografting, has inherent drawbacks, including limited availability and donor site morbidity. This leaves researchers seeking an alternative source of bone cells and makes bone tissue engineering a growing field with considerable translational potential.

"The success of induced pluripotent stem cell (iPSC) technology to reprogram fibroblasts into progenitor cells of various lineages offers an exciting route for tissue repair and regeneration," said Zufu Lu, Ph.D., a member of the University of Sydney's Biomaterials and Tissue Engineering Research Unit and a research associate at the ARC for Innovative BioEngineering. He is a co-lead investigator of the SCTM study, along with Professor Hala Zreiqat, Ph.D., head of the research unit and director of the ARC Training Centre for Innovative BioEngineering.

"However, while iPSC technology represents a potentially unlimited source of progenitor cells and allows patients to use their own cells for tissue repair and regeneration thus posing little or no risk of immune rejection the technology has several constraints. Among them are the requirement for complex reprogramming using the Yamanaka factors (Oct3/4, Sox2, Klf4, c-Myc). To add to the complexity, specific stimuli are required to direct iPSCs to re-differentiate to progenitor cells of the lineage of interest.

"In addition," Dr. Lu said, "any remaining iPSCs pose the risk of tumors following implantation."

One potential way around this, as demonstrated by recent studies, is through the direct reprogramming of fibroblasts into bone cells. "Fibroblasts are morphologically similar to osteoblasts. Their similar transcriptomic profiles led us to hypothesize that distinct factors produced by osteoblasts may be capable of coaxing fibroblasts to become osteoblast-like cells," Prof. Zreiqat said.

Previous studies aimed at using fibroblasts to produce various cell types relied on the genetic manipulation of one or more transcription regulators. But just as with iPSCs, reprogramming fibroblasts in this manner has its own inherent technical and safety issues. The Lu-Zreiqat team, however, surmised that an approach employing natural factors might just allow better control over reprogramming and improve the safety.

"Unlike genetic reprogramming, chemical induction of cell reprogramming is generally rapid and reversible, and is also more amenable to control through factor dosage and/or combinations with other molecules," Dr. Lu explained.

The team initially determined that media conditioned by human osteoblasts can induce reprogramming of human fibroblasts to functional osteoblasts. "Next," said Prof. Zreiqat, "our proteomic analysis identified a single naturally bioactive protein, insulin growth factor binding protein-7 (IGFBP7), as being significantly elevated in media conditioned with osteoblasts, compared to those with fibroblasts."

This led them to test IGFBP7's ability as a transcription factor. They found it, indeed, successfully induced a switch from fibroblasts to osteoblasts in vitro. They next tested it in a mouse model and once again experienced success when the fibroblasts produced mineralized tissue. The switch was associated with senescence and dependent on autocrine IL-6 signaling.

"The approach we describe in our study has significant advantages over other commonly used cell sources including iPSCs and adult mesenchymal stem cells," Dr. Lu and Prof Zreiqat concluded.

"Bone tissue engineering is a growing field where cell therapies have considerable translational potential, but current cell-based approaches face limitations," said Anthony Atala, M.D., Editor-in-Chief of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. "The novel observation described in this study could potentially lead to a shift in the current paradigm of bone regenerative medicine."

Story continues

This study was conducted in collaboration with the Charles Perkins Centre and the Children's Hospital at Westmead, University of Sydney.

The full article, "Reprogramming of human fibroblasts into osteoblasts by insulin-like growth factor binding protein 7," can be accessed at https://stemcellsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/sctm.19-0281.

About STEM CELLS Translational Medicine: STEM CELLS Translational Medicine (SCTM), co-published by AlphaMed Press and Wiley, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices. SCTM is the official journal partner of Regenerative Medicine Foundation.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals: STEM CELLS (http://www.StemCells.com), celebrating its 38th year, is the world's first journal devoted to this fast paced field of research. The Oncologist (http://www.TheOncologist.com), also a monthly peer-reviewed publication, entering its 25th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.

About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.wiley.com.

About Regenerative Medicine Foundation (RMF): The non-profit Regenerative Medicine Foundation fosters strategic collaborations to accelerate the development of regenerative medicine to improve health and deliver cures. RMF pursues its mission by producing its flagship World Stem Cell Summit, honouring leaders through the Stem Cell and Regenerative Medicine Action Awards, and promoting educational initiatives.

SOURCE STEM CELLS Translational Medicine

Read more:

New protocol could signal shift in bone regenerative medicine - Yahoo Finance

Read more
Stem Cells Market Segmentation and Analysis Report, 2025 – Food & Beverage Herald

In theglobalstem cells marketa sizeable proportion of companies are trying to garner investments from organizations based overseas. This is one of the strategies leveraged by them to grow their market share. Further, they are also forging partnerships with pharmaceutical organizations to up revenues.

In addition, companies in the global stem cells market are pouring money into expansion through multidisciplinary and multi-sector collaboration for large scale production of high quality pluripotent and differentiated cells. The market, at present, is characterized by a diverse product portfolio, which is expected to up competition, and eventually growth in the market.

Some of the key players operating in the global stem cells market are STEMCELL Technologies Inc., Astellas Pharma Inc., Cellular Engineering Technologies Inc., BioTime Inc., Takara Bio Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics Inc., Cytori Therapeutics, Inc., Osiris Therapeutics, Inc., and Caladrius Biosciences, Inc.

Request PDF Sample of Stem Cells Market Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=132

As per a report by Transparency Market Research, the global market for stem cells is expected to register a healthy CAGR of 13.8% during the period from 2017 to 2025 to become worth US$270.5 bn by 2025.

Depending upon the type of products, the global stem cell market can be divided into adult stem cells, human embryonic stem cells, induced pluripotent stem cells, etc. Of them, the segment of adult stem cells accounts for a leading share in the market. This is because of their ability to generate trillions of specialized cells which may lower the risks of rejection and repair tissue damage.

Depending upon geography, the key segments of the global stem cells market are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. At present, North America dominates the market because of the substantial investments in the field, impressive economic growth, rising instances of target chronic diseases, and technological progress. As per the TMR report, the market in North America will likely retain its dominant share in the near future to become worth US$167.33 bn by 2025.

Enquiry for Discount on Stem Cells Market Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=132

Investments in Research Drives Market

Constant thrust on research to broaden the utility scope of associated products is at the forefront of driving growth in the global stem cells market. Such research projects have generated various possibilities of different clinical applications of these cells, to usher in new treatments for diseases.Since cellular therapies are considered the next major step in transforming healthcare, companies are expanding their cellular therapy portfolio to include a range of ailments such as Parkinsons disease, type 1 diabetes, spinal cord injury, Alzheimers disease, etc.

The growing prevalence of chronic diseases and increasing investments of pharmaceutical and biopharmaceutical companies in stem cell research are the key driving factors for the stem cells therapeutics market. The growing number of stem cell donors, improved stem cell banking facilities, and increasing research and development are other crucial factors serving to propel the market, explains the lead analyst of the report.

This post was originally published on Food and Beverage Herald

See the original post here:

Stem Cells Market Segmentation and Analysis Report, 2025 - Food & Beverage Herald

Read more
Europe midday: Stocks track gains on Wall Street, drug and biotech shares higher – ShareCast

Stocks in the rest of Europe were putting in a small bounce on Tuesday, with investors taking their cue from US markets, which had finished higher the day before on the hope that the worst scenarios in the Middle East could yet be averted.

That was despite the head of Iran's national security council, Ali Shamkhani's, reported threat of a "historic nightmare" for the US.

"Even though tensions between the US and Iran remain high, sentiment in equity markets has turned positive, as European indices are showing modest gains this morning. The fact US markets ended yesterdays session higher paved the way for buying in Asia overnight as well as in Europe this morning," said David Madden, market analyst at CMC Markets UK.

"The gains might be limited seeing as the political situation is far resolved but it would appear that some of the fear has evaporated for now."

As of 1225 GMT, the benchmark Stoxx 600 was rallying 0.40% to 418.25, alongside a 0.87% jump to 13,241.60 for Germany's Dax, alongside a gain of 0.19% to 9,618.5 for the Spanish Ibex 35.

February gold futures on COMEX meanwhile were essentially flat, adding 0.01% to $1,569.0/oz., while the yield on the benchmark 10-year bund - another of investors' favourite safe havens - was steady at -0.29%.

As an aside, analysts at UBS bumped up their year-end target for the US S&P 500 from 3,000 to 3,250, telling clients that the Fed interest rate cuts in 2019 had sown the seeds for the next economic recovery, with GDP likely to trough later in 2020.

Pandora was again in the lead on the Stoxx 600, having guided towards the higher end of its previous guidance for its full-year EBIT margins the day before. In an unexpected trading update, released during the previous session, the jewellery-maker also posted a fourth quarter drop in like-for-like sales of 4.0% (JP Morgan: -7.0%), which followed a 11.0% fall in the third quarter.

Ipsen was right behind on the leaderboard after the UK's drug regulator approved the company's Dysport drug for the symptomatic treatment of upper limb spasticity in children suffering from cerebral palsy.

In parallel, Germany's Evotec SE got a boost from news that Bristol Myers Squibb had paid it $6.0m as part of yet another expansion of its collaboration on Induced Pluripotent Stem Cells.

Stock in Norwegian Air Shuttle ASA was also moving higher after reporting a 21% jump in revenues for December, which marked a ninth straight monthly increase.

On the economic side of things, traders' attention was on a parliamentary vote in Madrid, which was expected to see the incumbent Socialist Prime Minister, Pedro Sanchez, clinch the backing that he needed to form a minority coalition government, albeit with just a razor thin simple majority of MPs votes.

Elsewhere, Eurostat confirmed that the year-on-year rate of increase in Eurozone consumer prices picked up from a 1.0% pace in November to 1.3% in December.

Later in the session, investors will shift their attention to the release of the Institute for Supply Management's factory sector Purchasing Managers' Index covering the month of December, at 1600 GMT.

Read more:

Europe midday: Stocks track gains on Wall Street, drug and biotech shares higher - ShareCast

Read more
Stem Cell Banking Market 2020 Size, Share Metrics, Growth Trends and Forecast to 2026 – Food & Beverage Herald

New Jersey, United States, Verified Market Research indicates that the Stem Cell Banking Market is expected to surge at a steady rate in the coming years, as economies flourish. The research report, titled [Global Stem Cell Banking Market Research Report 2020], provides a comprehensive review of the global market. Analysts have identified the key drivers and restraints in the overall market. They have studied the historical milestones achieved by the Global Stem Cell Banking Market and emerging trends. A comparison of the two has enabled the analysts to draw a potential trajectory of the Global Stem Cell Banking Market for the forecast period.

Global Stem Cell Banking Market was valued at USD 1.47 billion in 2016 and is projected to reach USD 7.52billion by 2025, growing at a CAGR of 19.89% from 2017 to 2025.

Request a Sample Copy of this report @https://www.verifiedmarketresearch.com/download-sample/?rid=23773&utm_source=FHN&utm_medium=002

Top 10 Companies in the Global Stem Cell Banking Market Research Report:

Global Stem Cell Banking Market: Competitive Landscape

Competitive landscape of a market explains strategies incorporated by key players of the market. Key developments and shift in management in the recent years by players has been explained through company profiling. This helps readers to understand the trends that will accelerate the growth of market. It also includes investment strategies, marketing strategies, and product development plans adopted by major players of the market. The market forecast will help readers make better investments.

Global Stem Cell Banking Market: Drivers and Restrains

This section of the report discusses various drivers and restrains that have shaped the global market. The detailed study of numerous drivers of the market enable readers to get a clear perspective of the market, which includes market environment, government policies, product innovations, breakthroughs, and market risks.

The research report also points out the myriad opportunities, challenges, and market barriers present in the Global Stem Cell Banking Market. The comprehensive nature of the information will help the reader determine and plan strategies to benefit from. Restrains, challenges, and market barriers also help the reader to understand how the company can prevent itself from facing downfall.

Global Stem Cell Banking Market: Segment Analysis

This section of the report includes segmentation such as application, product type, and end user. These segmentations aid in determining parts of market that will progress more than others. The segmentation analysis provides information about the key elements that are thriving the specific segments better than others. It helps readers to understand strategies to make sound investments. The Global Stem Cell Banking Market is segmented on the basis of product type, applications, and its end users.

Global Stem Cell Banking Market: Regional Analysis

This part of the report includes detailed information of the market in different regions. Each region offers different scope to the market as each region has different government policy and other factors. The regions included in the report are North America, South America, Europe, Asia Pacific, and the Middle East. Information about different region helps the reader to understand global market better.

Ask for Discount @https://www.verifiedmarketresearch.com/ask-for-discount/?rid=23773&utm_source=FHN&utm_medium=002

Table of Content

1 Introduction of Stem Cell Banking Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Stem Cell Banking Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Stem Cell Banking Market, By Deployment Model

5.1 Overview

6 Stem Cell Banking Market, By Solution

6.1 Overview

7 Stem Cell Banking Market, By Vertical

7.1 Overview

8 Stem Cell Banking Market, By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Stem Cell Banking Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Request Customization of Report @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Banking-Market/?utm_source=FHN&utm_medium=002

Highlights of Report

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]om

This post was originally published on Food and Beverage Herald

Read more:

Stem Cell Banking Market 2020 Size, Share Metrics, Growth Trends and Forecast to 2026 - Food & Beverage Herald

Read more
Cord Stem Cell banking Market Size, Share, Emerging Trends, Competitive Landscape, Segmentation And Growth Forecast 2026 – BulletintheNews

Global Cord stem cell banking marketis estimated to reach USD 13.8 billion by 2026 registering a healthy CAGR of 22.4%. The increasing number of parents storing their childs cord blood, acceptance of stem cell therapeutics, high applicability of stem cells are key driver to the market.

Cord stem cells bankingis nothing but the storing of the cord blood cell contained in the umbilical cord and placenta of a newborn child. This cord blood contains the stem cells which can be used in future to treat disease such as leukemia, thalassemia, autoimmune diseases, and inherited metabolic disorders, and few others.

Few of the major market competitors currently working in the global cord stem cell banking market are CBR Systems, Inc., Cordlife, Cells4Life Group LLP, Cryo-Cell International, Inc., Cryo-Save AG, Lifecell, StemCyte India Therapeutics Pvt. Ltd, Viacord, SMART CELLS PLUS., Cryoviva India, Global Cord Blood Corporation, National Cord Blood Program, Vita 34, ReeLabs Pvt. Ltd., Regrow Biosciences Pvt. Ltd. , ACROBiosystems., Americord Registry LLC., New York Blood Center, Maze Cord Blood, GoodCell., AABB, Stem Cell Cryobank, New England Cryogenic Center, Inc. among others

Request for sample copy or PDF with (Market Segments, Forecast, Key players) @https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-cord-stem-cell-banking-market&raksh

Market Drivers

Market Restraint

Cord Stem Cell banking market research report gives specific analysis for the quickly changing elements of the business. The primary goal of the report is to comprehend the future standpoint and prospect of the Industry. Talented market researchers examines the entire market scenario and have helped to form this first class Cord Stem Cell banking report and they have performed inside-out data social affair practices on a tremendous scale premise. This research report additionally gives detail investigation on the flow applications and relative examination with progressively centered on the upstream and downstream of focused market.

The Cord Stem Cell banking market research report gives a clear perspective regarding the changing market patterns and trends. If you want your organization to grow in this highly competitive market scenario, then this Cord Stem Cell banking market report undoubtedly will meet your requirements. It not only highlights the crucial market factors that are currently emerging in the market but also discusses the future conjecture for the estimated time frame. The best part of the report is it is easy to understand as various information of the Cord Stem Cell banking market is bifurcated into segments based on the products, product type, area and key manufacturers.

Browse Detailed TOC, Tables, Figures, Charts and Companies @https://www.databridgemarketresearch.com/toc?dbmr=global-cord-stem-cell-banking-market&raksh

Segmentation: Global Cord Stem Cell Banking Market

By Storage Type

By Product Type

By Service Type

By Indication

By Source

Key Developments in the Market:

Competitive Analysis: Global Cord Stem Cell Banking Market

Global cord stem cell banking market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions and others to increase their footprints in this market. The report includes market shares of cord stem cell banking market for Global, Europe, North America, Asia Pacific, South America and Middle East & Africa.

Want Full Report? Enquire Here @https://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-cord-stem-cell-banking-market&raksh

About Data Bridge Market Research :

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us :

Data Bridge Market ResearchOffice Number 402,Amanora Chambers,Magarpatta Road, HadapsarPune 411028Maharashtra, India.

Toll Free: +1-888-387-2818

[emailprotected]

See more here:

Cord Stem Cell banking Market Size, Share, Emerging Trends, Competitive Landscape, Segmentation And Growth Forecast 2026 - BulletintheNews

Read more
ThermoGenesis Holdings Announces That ImmuneCyte Joint Venture Receives $3.0 Million Equity Investment – P&T Community

RANCHO CORDOVA, Calif., Jan. 3, 2020 /PRNewswire/ --ThermoGenesis Holdings, Inc.(Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that ImmuneCyte Life Sciences, Inc. ("ImmuneCyte"), an 80/20 joint venture between HealthBanks Biotech (USA) and ThermoGenesis, has closed a $3.0 million equity investment with a private institution. The investor received 600,000 shares of Class A common stock at $5.00 per share, representing a 5.66% ownership in the joint venture. As a result of this equity investment in ImmuneCyte, ThermoGenesis' equity in the joint venture is no longer subject to the anti-dilution provision. After this investment, ImmuneCyte is owned 75.47% by HealthBanks Biotech (USA), 18.87% by ThermoGenesis Holdings and 5.66% by the private institution.

ImmuneCyte is a joint venture which was created in order to provide immune cell banking services to healthy customers, enabling them to store their healthy immune cells for potential future use in immunotherapies, leveraging ThermoGenesis' proprietary CAR-TXpress platform and HealthBanks' global, stem cell banking network. ImmuneCyte isolates healthy immune cells from 150-200ml of peripheral blood with a proprietary, automated cell processing platform developed by ThermoGenesis, which makes ImmuneCyte the first cell bank capable of processing immune cells under a functionally-closed and fully cGMP compliant environment, a quality control element which is essential for cell and gene therapies.

"The rapid closing of this equity investment in ImmuneCyte, only shortly after the establishment of the joint venture, reflects a significant interest in ThermoGenesis' proprietary technology and the growth potential of ImmuneCyte's business model," said Chris Xu, PhD, Chief Executive Officer of ThermoGenesis. "We are excited by this latest investment, which will allow the joint venture to further accelerate its growth, while serving to increase the value of ThermoGenesis' equity stake in the joint venture, long-term."

About ImmuneCyte Life Sciences, Inc.ImmuneCyte will provide clients with the opportunity to bank their own immune cells when the cells are "healthy and unaffected," as a future resource for cellular immunotherapies, such as CAR-T. ImmuneCyte utilizes ThermoGenesis' proprietary CAR-TXpress platform, a GMP compliant closed-system capable of automated separation and cryopreservation of different components from blood. For more information about ImmuneCyte Life Sciences Inc., please visit: http://www.immunecyte.com.

About ThermoGenesis Holdings, Inc.ThermoGenesis Holdings, Inc., formerly known as Cesca Therapeutics Inc.,develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpressplatform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, pleasevisit: http://www.ThermoGenesis.com.

Company Contact:Wendy Samford916-858-5191ir@ThermoGenesis.com

Investor Contact:Paula Schwartz,Rx Communications917-322-2216pschwartz@rxir.com

View original content:http://www.prnewswire.com/news-releases/thermogenesis-holdings-announces-that-immunecyte-joint-venture-receives-3-0-million-equity-investment-300980674.html

SOURCE ThermoGenesis Holdings, Inc.

Excerpt from:

ThermoGenesis Holdings Announces That ImmuneCyte Joint Venture Receives $3.0 Million Equity Investment - P&T Community

Read more
Stem Cells Market in The Region Is Anticipated To Expand At a CAGR of 13.8% During the Period from 2017 to 2025 – Market Research Sheets

In theglobal stem cells marketa sizeable proportion of companies are trying to garner investments from organizations based overseas. This is one of the strategies leveraged by them to grow their market share. Further, they are also forging partnerships with pharmaceutical organizations to up revenues.

In addition, companies in the global stem cells market are pouring money into expansion through multidisciplinary and multi-sector collaboration for large scale production of high quality pluripotent and differentiated cells. The market, at present, is characterized by a diverse product portfolio, which is expected to up competition, and eventually growth in the market.

Some of the key players operating in the global stem cells market are STEMCELL Technologies Inc., Astellas Pharma Inc., Cellular Engineering Technologies Inc., BioTime Inc., Takara Bio Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics Inc., Cytori Therapeutics, Inc., Osiris Therapeutics, Inc., and Caladrius Biosciences, Inc.

As per a report by Transparency Market Research, the global market for stem cells is expected to register a healthy CAGR of 13.8% during the period from 2017 to 2025 to become worth US$270.5 bn by 2025.

Request a Sample of Stem Cells Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=132

Depending upon the type of products, the global stem cell market can be divided into adult stem cells, human embryonic stem cells, induced pluripotent stem cells, etc. Of them, the segment of adult stem cells accounts for a leading share in the market. This is because of their ability to generate trillions of specialized cells which may lower the risks of rejection and repair tissue damage.

Depending upon geography, the key segments of the global stem cells market are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. At present, North America dominates the market because of the substantial investments in the field, impressive economic growth, rising instances of target chronic diseases, and technological progress. As per the TMR report, the market in North America will likely retain its dominant share in the near future to become worth US$167.33 bn by 2025.

Investments in Research Drives Market

Constant thrust on research to broaden the utility scope of associated products is at the forefront of driving growth in the global stem cells market. Such research projects have generated various possibilities of different clinical applications of these cells, to usher in new treatments for diseases.Since cellular therapies are considered the next major step in transforming healthcare, companies are expanding their cellular therapy portfolio to include a range of ailments such as Parkinsons disease, type 1 diabetes, spinal cord injury, Alzheimers disease, etc.

Request for a Discount on Stem Cells Market Report -.

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=132

The growing prevalence of chronic diseases and increasing investments of pharmaceutical and biopharmaceutical companies in stem cell research are the key driving factors for the stem cells therapeutics market. The growing number of stem cell donors, improved stem cell banking facilities, and increasing research and development are other crucial factors serving to propel the market, explains the lead analyst of the report.

This review is based on the findings of a TMR report, titled, Stem Cells Market (Product Adult Stem Cell, Human Embryonic Stem Cell, and Induced Pluripotent Stem; Sources Autologous and Allogeneic; Application Regenerative Medicine and Drug Discovery and Development; End Users Therapeutic Companies, Cell and Tissues Banks, Tools and Reagent Companies, and Service Companies) Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 20172025.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY 12207United StatesTel:+1-518-618-1030USA Canada Toll Free:866-552-3453Email:[emailprotected]Website:http://www.transparencymarketresearch.com

This post was originally published on Market Research Sheets

Go here to see the original:

Stem Cells Market in The Region Is Anticipated To Expand At a CAGR of 13.8% During the Period from 2017 to 2025 - Market Research Sheets

Read more